In future, it is possible that up to 46% of patients who would have received chemotherapy in the past could be spared from this treatment and its side effects.
The first results of the MINDACT trial give hope to many women with early-stage breast cancer.
Discover in the last BIG annual report, the success story of an academic trial that has the potential to change the future of breast cancer treatment.
BIG is an international non-profit organisation for academic breast cancer research groups from around the world. The association is the most extensive global research network dedicated solely to breast cancer. BIG encompasses 55 member groups worldwide, which are breast cancer focused collaborative research groups or data centres.
Global collaboration is crucial to make significant advances in breast cancer research, reducing unnecessary duplication of effort, sharing data and enabling collaboration of scientists across borders, contributing to the faster development of better treatments, and increasing the likelihood of cures for patients.
Page in extremis is happy to participate in the creative development and the graphical production of the BIG’s annual report. The result is a vibrant publication made within an intimate inventive dialogue framework involving the Belgian communication agency’s creative team and the BIG’s communication team.
Page in extremis is specialised in communication with sensitive issues. The communication agency creates and refreshes human-centred brands and develops percussive digital and classic media.
The communication agency has defined a very accurate process including monitoring and quality check particularly suited to provide maximum comfort to its clients and the best results.
Each year, the team of Page in extremis signs the design and produces about twenty annual reports.
Since 1994, the broad experience of the communication agency has been extended to more than four hundred annual reports.
Be surprised by our know-how, contact us!
More information:
http://www.inextremis.be